Pharmacological inhibition from the ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR; also known as FRAP-relevant protein (FRP1)) has emerged for a promising tactic for cancer treatment that exploits synthetic lethal interactions with proteins involved in DNA damage repair, overcomes resistance to other therapies and enhances antitumour immunity. Various novel, https://kirkk776zlv0.elbloglibre.com/profile